Core Insights - Vivos Therapeutics has achieved 'in-network' status with several major health insurance payers in Nevada, enhancing patient access to its obstructive sleep apnea (OSA) treatments and potentially increasing revenue and profitability [1][2][3][4] - The company is implementing cost reduction initiatives aimed at its legacy business model, which are expected to save approximately $4 million annually, thereby reducing cash burn and moving towards cash flow positivity in fiscal year 2026 [5][12] Insurance Coverage - Vivos' physician-owned practices in Nevada have gained 'in-network' status with multiple health insurance providers, including Medicare, UnitedHealthcare, and Aetna, which cover a significant portion of the Las Vegas metropolitan area population [3][4] - This development is anticipated to improve patient access to Vivos' patented OSA treatments, allowing previously evaluated patients to be contacted regarding insurance coverage availability [4] Cost Reduction Initiatives - The company has initiated a series of cost reduction measures, including workforce reduction and restructuring vendor relationships, to streamline operations related to its legacy dental-focused distribution model [5] - These initiatives are projected to yield around $4 million in annual savings, which will help in reducing the company's cash burn rate [5][12] Market Context - OSA affects over 1 billion people globally, with a significant portion remaining undiagnosed, highlighting the ongoing need for effective treatment solutions [8] - Vivos aims to address the complexities of OSA treatment through innovative technology and collaborations with healthcare providers, moving away from traditional CPAP treatments [9][10]

Core Viewpoint - Vivos Therapeutics, Inc. has announced that a recent study supports its belief that dental and facial morphology is directly correlated to the prevalence and severity of obstructive sleep apnea (OSA) in both adults and children [1][3]. Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues related to dentofacial abnormalities such as OSA and snoring [9]. - The company’s CARE devices have received FDA clearance for treating all severity levels of OSA in adults and moderate-to-severe OSA in children aged 6 to 17 [9]. Study Findings - The study titled "Correlation Between Severity of Obstructive Sleep Apnea and Dental Arch Form in Adults" indicates that small changes in dental and jaw morphology can lead to significant changes in airway function, with narrower intermolar distance and greater palatal height linked to higher Apnea-Hypopnea Index (AHI) [3][4]. - The study involved 100 participants, with the OSA group showing significantly narrower transverse intermolar distance and higher palatal height compared to controls, demonstrating a strong association (p<0.001) between these parameters and OSA severity [4]. Treatment Efficacy - Vivos-trained providers have successfully treated tens of thousands of OSA patients using Vivos CARE devices, with many patients completing treatment in less than 12 months and experiencing little to no remaining OSA symptoms [2]. - The unique mechanism of action in Vivos CARE devices allows for gradual redevelopment and repositioning of dental arches and jaws, potentially leading to lasting results [5]. Market Context - OSA affects over 1 billion people globally, with 80% remaining undiagnosed. The condition is linked to various chronic health issues, and traditional treatments like CPAP often fail to address root causes [10]. - The company estimates that several million Americans will undergo sleep tests this year, with nearly half likely to test positive for OSA, highlighting a significant market opportunity for Vivos devices [8].

Core Viewpoint - Vivos Therapeutics has announced a collaboration with SoundHealth to enhance public awareness and access to innovative airway and sleep health technologies, aiming to improve treatment for breathing-related sleep disorders [1][2][3] Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for breathing and sleep issues, particularly obstructive sleep apnea (OSA) [10][12] - The company has FDA clearance for its devices, which are designed for both adults and children suffering from various severity levels of OSA [10][11] Collaboration Details - The partnership will utilize Vivos' network of over 2,000 trained dentists and sleep healthcare providers to distribute SoundHealth's Sonu® platform, which includes the FDA-cleared Sonu® Band and the new Spatial Sleep™ band [2][3] - SoundHealth's products employ personalized vibro-acoustic neuromodulation to enhance nasal breathing and promote restful sleep [2][4] Product Innovations - The Sonu Band is recognized as the first FDA-cleared AI-enabled wearable for treating nasal congestion, comparable to intranasal steroids, and has been shown to improve CPAP user compliance [4] - The Spatial Sleep band utilizes personalized acoustic resonance therapy to facilitate quicker sleep onset and longer sleep duration through active neural entrainment [5] Technology Utilization - SoundHealth's technology includes a smartphone camera-based facial scanning and voice biomarker system, which will assist Vivos' clinical providers in screening and monitoring sleep disorders [3][6] - The Sonu smartphone app tracks airway health in real-time, allowing for active patient monitoring throughout their treatment journey [6] Market Context - The global sleep technology sector is valued at approximately $30 billion, with a significant shift from passive monitoring to active airway interventions [8] - There is a high prevalence of undiagnosed sleep-disordered breathing, with nearly 80% of cases remaining unrecognized, highlighting the need for innovative treatment solutions [8][9] Health Implications - Untreated sleep-disordered breathing is linked to a 140% increased risk of heart failure and a 30% higher risk of coronary heart disease, emphasizing the importance of airway health in overall wellness [7]

Core Viewpoint - Vivos Therapeutics has announced a collaboration with SoundHealth to enhance public awareness and access to innovative airway and sleep health technologies, aiming to improve treatment for breathing-related sleep disorders [1][2][3] Group 1: Collaboration Details - The partnership will utilize Vivos' network of over 2,000 trained dentists and sleep healthcare providers to distribute SoundHealth's Sonu platform, which includes the FDA-cleared Sonu® Band and the new Spatial Sleep™ band [2][3] - Vivos will act as a reseller for SoundHealth's products, leveraging SoundHealth's extensive craniofacial dataset and technology for educational and distribution initiatives [3] Group 2: Product Information - The Sonu Band is the first FDA-cleared AI-enabled wearable for treating nasal congestion, comparable to intranasal steroids, and has no side effects [4] - The Spatial Sleep band uses personalized acoustic resonance therapy to promote rapid sleep onset and longer sleep duration through active neural entrainment [5] - Both devices utilize smartphone cameras to create a CT-quality anatomical model for personalized therapeutic stimulation [5] Group 3: Health Impact and Market Insights - The collaboration addresses significant health risks, as untreated sleep-disordered breathing is linked to a 140% increased risk of heart failure and a 30% higher risk of coronary heart disease [7] - The global sleep technology market is valued at approximately $30 billion, with a shift from passive tracking to active airway interventions, highlighting the need for better diagnosis and treatment of sleep disorders [8][9] - Over 1 billion people are affected by obstructive sleep apnea (OSA), with 80% remaining undiagnosed, indicating a substantial market opportunity for innovative treatments [11]

Core Insights - The health care sector has identified oversold stocks, presenting potential investment opportunities in undervalued companies [1] - The Relative Strength Index (RSI) is a key momentum indicator used to assess stock performance, with an RSI below 30 indicating that a stock is considered oversold [1] Oversold Stocks List - Zai Lab Ltd – ADR (NASDAQ:ZLAB) is among the major oversold players in the health care sector [3] - Vivos Therapeutics Inc (NASDAQ:VVOS) is also listed as an oversold stock [3] - Certara Inc (NASDAQ:CERT) is included in the list of oversold companies [3]

Core Insights - The health care sector has identified oversold stocks, presenting potential investment opportunities in undervalued companies [1] - The Relative Strength Index (RSI) is a key momentum indicator used to assess stock performance, with an RSI below 30 indicating that a stock is considered oversold [1] Oversold Stocks - Zai Lab Ltd – ADR (NASDAQ:ZLAB) is listed as one of the major oversold players in the health care sector [3] - Vivos Therapeutics Inc (NASDAQ:VVOS) is also identified as an oversold stock with an RSI near or below 30 [3] - Certara Inc (NASDAQ:CERT) is included in the list of oversold stocks, indicating potential for recovery [3]

Core Viewpoint - Vivos Therapeutics, Inc. has successfully closed the exercise of outstanding warrants, raising approximately $4.64 million to support its operations in the sleep-related breathing disorder market, particularly obstructive sleep apnea (OSA) [1][4]. Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues, particularly OSA and snoring [7]. - The company’s devices have received FDA clearance for treating OSA in adults and children aged 6 to 17, with its Complete Airway Repositioning and Expansion (CARE) devices being the only FDA 510(k) cleared technology for severe OSA in adults [7]. Market Context - OSA affects over 1 billion people globally, with 90% remaining undiagnosed, highlighting a significant market opportunity for innovative treatments [8]. - Traditional treatments like CPAP often fail to address the root causes of OSA, indicating a need for more effective solutions [8]. Financial Activity - The company exercised warrants to purchase up to 1,982,356 shares at a reduced price of $2.34 per share, originally priced between $3.83 and $5.05 [1]. - In exchange for the cash exercise of existing warrants, Vivos issued new unregistered warrants to purchase up to 3,964,712 shares at an exercise price of $2.09 per share [3]. Use of Proceeds - The net proceeds from the warrant exercise will be utilized for working capital and general corporate purposes [4].

Core Viewpoint - Vivos Therapeutics, Inc. has entered into a definitive agreement for the immediate exercise of outstanding warrants, which will generate approximately $4.64 million in gross proceeds for the company [1][4]. Group 1: Financial Details - The company will exercise warrants to purchase up to 1,982,356 shares at a reduced exercise price of $2.34 per share, down from original prices ranging from $3.83 to $5.05 [1]. - In exchange for the cash exercise of existing warrants, Vivos will issue new unregistered warrants to purchase up to 3,964,712 shares at an exercise price of $2.09 per share [3]. - The offering is expected to close on or about January 20, 2026, subject to customary closing conditions [4]. Group 2: Company Overview - Vivos Therapeutics focuses on developing and commercializing innovative diagnostic and treatment methods for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [7]. - The company’s devices are FDA-cleared for treating OSA in both adults and children, with its Complete Airway Repositioning and Expansion (CARE) devices being the only FDA 510(k) cleared technology for severe OSA in adults [7]. - OSA affects over 1 billion people globally, with 90% undiagnosed, highlighting a significant market opportunity for Vivos [8]. Group 3: Strategic Intent - Vivos aims to empower healthcare providers to address the complex needs of OSA patients through innovative technology, education, and collaborations with sleep healthcare providers [9]. - The company promotes its treatment approach, known as The Vivos Method, which is a nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [10].

Core Viewpoint - Vivos Therapeutics, Inc. (VVOS) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates in determining near-term stock price movements, making it a valuable tool for investors [2][4]. - The correlation between earnings estimate revisions and stock price movements is strong, with institutional investors using these estimates to assess fair value [4]. Company Performance and Investor Sentiment - The upgrade in Vivos Therapeutics' rating reflects an improvement in the company's underlying business, which is expected to positively influence its stock price [5]. - Analysts have raised their earnings estimates for Vivos Therapeutics, with the Zacks Consensus Estimate increasing by 11.9% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - Vivos Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Company Overview - Vivos Therapeutics is a revenue stage medical technology company focused on developing and commercializing innovative diagnostic and nonsurgical treatment methods for patients with breathing and sleep issues, particularly obstructive sleep apnea (OSA) [2] - OSA is estimated to affect approximately 90 million people in the U.S. and 1 billion people worldwide, highlighting a significant market opportunity for Vivos [2] Leadership and Presentation - The fireside chat features Kirk Huntsman, CEO of Vivos Therapeutics, and Brad Amman, CFO, indicating the company's commitment to engaging with stakeholders and sharing insights about its operations [3]